AGC's New Bioreactors and Microbial Facility for Increased Productivity
By MedTech Outlook | Wednesday, February 27, 2019
Biopharmaceutical production is characterized by the use of advanced technologies, exploring new scientific advances and complex R&D enterprise. The development of a new compound requires large investments in time and capital to translate scientific discovery into new medicine.
AGC Inc. is one of the companies of the AGC Group, a leading provider of flat, automotive, display glass, chemicals, ceramics, and other high-tech materials and components for glass solutions. The company offers a wide range of products to customers in a wide range of industries through world-leading technologies.
AGC Inc. has announced its major expansion plan for AGC Biologics, headquartered in the U.S. The company is going to install 12 additional single-use animal cell bioreactors at its Seattle AGC Biologics site. They are also going to establish a new contract development and manufacturing facility for microbial production, previously operating only in Europe and Japan. AGC Biologics is the company’s CDMO subsidiary. The expansion is expected to triple the biopharmaceutical production capacity of AGC in the USA while ensuring the seamless operation of biopharmaceutical CDMO activities. The investment for this expansion is estimated to be $90 million, with full operations scheduled for July 2020.
As part of a plan to increase its sales in the life sciences sector to $800 million by 2025, AGC is boosting its biotech drug manufacturing business contract. It recently purchased two contract manufacturers: the German Biomeva company in 2016 and the CMC Biologics company in Denmark in 2017.
AGC plans to continue to pursue acquisition opportunities and invest capital in its synthetic and biopharmaceutical business. It is expected to show significant growth in demand in the coming years, in order to continue to provide global quality and service to customers in each region. By maximizing synergies between its sites, AGC will continue to pursue its objective of being a company that contributes to pharmaceutical companies, medical patients, and the general public.